Verona Pharma (VRP)
VRP Share PerformanceMore
|52 week high||210.00 24/10/16|
|52 week low||120.75 17/02/17|
|52 week change||-28.25 (-17.52%)|
|4 week volume||309,999 04/04/17|
Media for (VRP)
Latest News« previous» nextMore
28/04/2017 - 17:50 StockMarketWire
Dr David Ebsworth, Chairman, 13,373 shares in the company on the 27th April 2017 at a price of 132.00p. The Director now...
28/04/2017 - 17:40 RNS
RNS Number: 7827D Verona Pharma PLC 28 April 2017 Verona Pharma Announces Director Purchases and Related Party Transactions April 28, 2017, LONDON - Verona Pharma plc (AIM: VRP) ("Verona Pharma"), a clinical-stage biopharmaceutical company focused on developing and commercialising innovative therapeutics for the treatment of respiratory dis...
27/04/2017 - 07:00 RNS
RNS Number: 4835D Verona Pharma PLC 27 April 2017 THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014 NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN OR INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOU...
19/04/2017 - 07:00 RNS
RNS Number: 6578C Verona Pharma PLC 19 April 2017 THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014 Verona Pharma Announces Launch of Global Offering and Application to List on the NASDAQ Global Market 19 April 2017, London - Verona Pharma plc (AIM: V...
18/04/2017 - 07:19 StockMarketWire
Verona Pharma announced the US Food and Drug Administration (FDA) authorized the initiation of a pharmacokinetic ...
18/04/2017 - 07:00 RNS
RNS Number: 5435C Verona Pharma PLC 18 April 2017 THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION FOR THE PURPOSES OF ARTICLE 7 OF REGULATION (EU) NO 596/2014. Verona Pharma Receives Authorization from the U.S. FDA to Proceed with Clinical Investigation of RPL554 with the Acceptance of Investigational New Drug Applic...
12/04/2017 - 13:21 StockMarketWire
Verona Pharma has confirmed that all resolutions proposed at the Annual General Meeting (AGM) held today were duly ...
12/04/2017 - 13:19 RNS
RNS Number: 3537C Verona Pharma PLC 12 April 2017 Verona Pharma plc ("Verona Pharma" or the "Company") Result of AGM 12 April 2017, London -Verona Pharma plc (AIM: VRP.L), a clinical-stage biopharmaceutical company focused on developing and commercialising innovative therapeutics for the treatment of respiratory diseases, announces that all reso...
|Dividend yield||0 %|
Equity Research (VRP)
Verona Pharma plc
Verona’s £44.7m gross raise removes funding uncertainty, allowing the company to focus on the clinical progress of its respiratory asset RPL554, a dual PDE3/PDE4 inhibitor. RPL554 is in development...
Verona Pharma plc
VRP is developing first-in-class drugs to treat unmet medical needs in respiratory disease. Over the last two years’ VRP has reported positive outcomes from a five stage Phase I/IIa programme which...
Verona Pharma plc
VRP is developing first-in-class drugs that treat unmet medical needs in respiratory disease. RPL554 is being fast-tracked to commercialisation by focusing on a $3.2bn market segment poorly serviced...
- 1 of 2
Latest discussion posts More
“from which you will note latest filings 280417 lots in there - should you so wish to read over this long weekend or perhaps not - lol bw all mol”▼
“so we now know how much our Chairman's further investment was Dr David Ebsworth- 13,373 #17,652.36 total holding now 117,657 shares leaving 240,726 shares at 1.32 by an ...”▼
“now updated to show SEC Filings in addition to RNS http://investors.veronapharma.com/sec-filings mol”▼
Codes & Symbols
|Symbols||VRP, LSE:VRP, VRP.L, VRP:LN, LON:VRP, XLON:VRP|